Brief: Oncternal Therapeutics Announces First Patient Dosed In Phase 1/2 Study Of ROR1
06/06/2023 21:03
June 6 (Reuters) - Oncternal Therapeutics Inc ONCT.O :
* ONCTERNAL THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE
1/2 STUDY OF ROR1 TARGETING AUTOLOGOUS CAR T, ONCT-808, IN
PATIENTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL LYMPHOMA
* ONCTERNAL THERAPEUTICS INC - COMPANY EXPECTS TO PRESENT
INITIAL
CLINICAL DATA IN LATE 2023, WITH ADDITIONAL CLINICAL DATA
READOUTS IN 2024
Source text for Eikon: ID:nGNX76nslJ
Further company coverage: ONCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncternal Therapeutics
See all newsOncternal Therapeutics Inc expected to post a loss of $3.19 a share - Earnings Preview
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;